Anti-HSP90α antibodies and uses thereof

Novel anti-HSP90α antibodies target the tumor-promoting effects of eHSP90α, suppressing tumor growth and enhancing immune response in PDAC and CRC by blocking eHSP90α secretion and interaction, offering a promising therapeutic approach.

JP2024542238APending Publication Date: 2024-11-13NATIONAL HEALTH RESEARCH INSTITUTE
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024529897
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2021-11-22
Publication Date
2024-11-13

AI Technical Summary

Technical Problem

Current treatments for cancer, particularly pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer, are hindered by the tumor-promoting effects of extracellular heat shock protein 90 alpha (eHSP90α) secreted by cancer-associated fibroblasts and M2-polarized macrophages, which enhance tumor growth and immunosuppression.

Method used

Development of novel anti-HSP90α antibodies that specifically bind to the HSP90α epitope, inhibiting its interaction with cell surface receptors and disrupting the feedforward loop of eHSP90α expression and secretion, thereby blocking its tumor-promoting effects.

Benefits of technology

The anti-HSP90α antibodies effectively suppress tumor growth, reduce desmoplasia, and enhance immune response by targeting eHSP90α, demonstrating potential as a therapeutic strategy for various cancers, including PDAC and CRC, with improved efficacy when combined with gemcitabine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542238000004
    Figure 2024542238000004
  • Figure 2024542238000005
    Figure 2024542238000005
  • Figure 2024542238000006
    Figure 2024542238000006
Patent Text Reader

Abstract

Disclosed is an isolated antibody comprising a novel complementarity determining region capable of specifically binding to an HSP90α epitope, the novel complementarity determining region comprising two EDK sites, respectively, in the region of amino acids 235 to 244 and amino acids 251 to 260. Also disclosed are nucleic acid molecules corresponding to the antibody, pharmaceutical compositions comprising the antibody or the corresponding nucleic acid molecule, and methods of treating and monitoring cancer using the antibody.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to novel anti-HSP90α antibodies and uses thereof. More specifically, the present disclosure relates to novel isolated anti-HSP90α antibodies, pharmaceutical compositions comprising same, and methods of treating cancer with same. [Background technology]

[0002] Cancer development and progression depend not only on genetic and epigenetic changes in epithelial cells, but also on crucial changes in the stromal microenvironment of epithelial cells, which consists of the extracellular matrix (ECM) and stromal cells such as fibroblasts and immune cells. See Pandol S, Edderkaoui M, Gukovsky I, Lugea A, Gukovskaya A, Desmoplasia of pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol 2009;7(11):S44-7. Desmoplasia is a common feature of many malignancies, such as pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC), and results from the abundance of ECM and a large number of myofibroblasts that express α-smooth muscle actin (α-SMA) as a characteristic marker. Such myofibroblasts, also called activated fibroblasts or cancer-associated fibroblasts (CAFs), contribute to tumor growth, immune suppression, and malignant progression. Orimo A, Gupta PB, Sgroi DC, Arenazana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1 / CXCL12 secretion.Cell 2005;121(3):335-48, Lakins MA, Ghorani E, Munir H, Carla P. Martins CP, Shields JD, Cancer-associated fibroblasts induce antigen-specific deletion of CD8+ See, T cells to protect tumour cells. Nat Commun 2018;9(1):948; Turley SJ, Cremasco V, Astarita JL, Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol 2015;15(11):669-82; and Beacham DA, Cukierman E, Stromagenesis: the changing face of fibroblastic microenvironments during tumor progression. Semin Cancer Biol 2005;15(5):329-41. They constitute the majority of tumor stromal cells and can be derived from diverse sources, including tissue-resident fibroblasts, astrocytes, mesenchymal stem / progenitor cells and infiltrating fibrocytes. See Sugimoto H, Mundel TM, Kieran MW, Kalluri R, Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 2006;5(12):1640-6. In addition, CAFs can also arise from endothelial-mesenchymal transition (EndoMT) of endothelial cells. See Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R, Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 2007;67(21):10123-8. Our previous studies have demonstrated that EndoMT-derived CAFs (i.e., α-SMA + CD31 +Osteopontin-integrin engagement induces HIF-1α-TCF12-mediated endothelial-mesenchymal transition to exacerbate colorectal cancer. Oncotarget 2018;9(4):4998-5015. OPN induced EndoMT in endothelial cells, and the resulting EndoMT-derived CAFs exhibited potent tumor-promoting effects by secreting HSP90α and promoting stemness in CRC cells. See Fan CS, Chen WS, Chen LL, Chen CC, Hsu YT, Chua KV, et al. Osteopontin-integrin engagement induces HIF-1α-TCF12-mediated endothelial-mesenchymal transition to exacerbate colorectal cancer. Oncotarget 2018;9(4):4998-5015. Recently, we also found that mixtures of EndoMT-derived CAFs with PDAC cell grafts significantly recruit bone marrow-derived macrophages, prevent immune T cells, and promote tumor growth. See Fan CS, Chen LL, Hsu TA, et al. Endothelial-mesenchymal transition harnesses HSP90α-secreting M2-macrophages to exacerbate pancreatic ductal adenocarcinoma. J Hematol Oncol 2019;12:138. HSP90α secreted by EndoMT-derived CAFs further induced M2 polarization of macrophages and more HSP90α secretion through cell surface receptors CD91 and TLR4 and the downstream MyD88-JAK2 / TYK2-STAT-3 pathway.Fan CS, Chen LL, Hsu TA, et al. Endothelial-mesenchymal transition harnesses HSP90α-secreting M2-macrophages to exacerbate pancreatic ductal adenocarcinoma. J Hematol Oncol. 2019;12:138. Cited reference.

[0003] HSP90α is a known cellular chaperone that assists in the folding, maturation and trafficking of numerous client proteins, including cancer-associated Bcr-Abl, ErbB2 / Neu, Akt, HIF-1α, mutant p53 and Raf-1. See Trepel JB, Mollapour M, Giaccone G, Neckers L, Targeting the dynamic Hsp90 complex in cancer. Nat Rev Cancer 2010;10(8):537-49. It is also expressed and secreted by keratinocytes and fibroblasts in wounded tissues and by cancer cells in unfavorable microenvironments to promote epithelial-mesenchymal transition (EMT), migration, invasion and metastasis of cancer cells. Li W, Li Y, Guan S, Fan J, Cheng CF, Bright AM, et al., Extracellular heat shock protein-90α: linking hypoxia to skin cell motility and wound healing.EMBO J 2007;26(5):1221-33, Xu A, Tian T, Hao J, Liu J, Zhang Z, Hao J, et al., Elevation of serum HSP90α correlated with the clinical stage of See non-small cell lung cancer. J Cancer Mol 2007;3(4):107-12 and Wang X, Song Clinically, elevated serum / plasma HSP90α levels have been detected in several malignant tumors, including CRC and PDAC.Wang X, Song X, Zhuo W, Fu Y, Shi H, Liang Y, et al. The regulatory mechanism of HSP90α secretion and its function in tumor malignancy. Proc Natl Acad Sci USA 2009;106(50):21288-9, Wang X, Song X, Zhuo W, Fu Y, Shi H, Liang Y, et al. The regulatory mechanism of HSP90α secretion and its function in tumor malignancy. Proc Natl Acad Sci USA 2009;106(50):21288-93, Chen JS, Hsu YM, Chen CC, Chen LL, Lee CC, Huang TS, Secreted heat shock protein 90α induces colorectal cancer cell invasion through CD91 / LRP-1 and NF-κB-mediated integrin α. Vexpression. J Biol Chem 2010;285(33):25458-66 and Chen CC, Chen LL, Li CP, Hsu YT, Jiang SS, Fan CS, et al., Myeloid-derived macrophages and secreted HSP90α induce pancreatic ductal adenocarcinoma development. OncoImmunology 2018;7(5):e1424612. Such elevated levels of extracellular HSP90α (eHSP90α) can also be detected in patients with pancreatitis and in PDAC-developing activated K-Ras knock-in mice. Chen CC, Chen LL, Li CP, Hsu YT, Jiang SS, Fan CS, et al., Myeloid-derived macrophages and secreted HSP90α induce pancreatic ductal adenocarcinoma development. OncoImmunology 2018;7(5):e1424612. eHSP90α can be produced from pancreatic-infiltrating bone marrow-derived macrophages and stimulated pancreatic ductal epithelial cells to promote macrophage-associated PDAC development. See Chen CC, Chen LL, Li CP, Hsu YT, Jiang SS, Fan CS, et al. Myeloid-derived macrophages and secreted HSP90α induce pancreatic ductal adenocarcinoma development. OncoImmunology 2018;7(5):e1424612. Furthermore, HSP90α or recombinant HSP90α (rHSP90α) secreted by EndoMT-derived CAFs can induce a feed-forward loop of M2 marker expression and HSP90α secretion from macrophages, which may explain why M2-polarized macrophages trigger a microenvironment that is not only immunosuppressive and angiogenic but also eHSP90α-rich to enhance PDAC tumor growth and malignant progression.See Fan CS, Chen LL, Hsu TA, et al. Endothelial-mesenchymal transition harnesses HSP90α-secreting M2-macrophages to exacerbate pancreatic ductal adenocarcinoma. J Hematol Oncol 2019;12:138. Overall, eHSP90α plays an important role in both tumor initiation and malignant progression and may be considered as an important therapeutic target.

[0004] In our previous study, we synthesized a cell-impermeable small molecule HSP90α inhibitor targeting eHSP90α. See Chen CC, Chen LL, Li CP, Hsu YT, Jiang SS, Fan CS, et al. Myeloid-derived macrophages and secreted HSP90α induce pancreatic ductal adenocarcinoma development. OncoImmunology 2018;7(5):e1424612. It showed some inhibition level on tumorigenesis and metastasis of PDAC cells, but it was easily excreted outside the mouse body, and frequent administration caused splenomegaly in mice. Meanwhile, we obtained hopeful clues from using anti-HSP90α mouse monoclonal antibody. Our recent study revealed that anti-HSP90α antibody showed strong therapeutic efficacy against EndoMT-promoted and M2 macrophage-associated PDAC tumor growth. See Fan CS, Chen LL, Hsu TA, et al. Endothelial-mesenchymal transition harnesses HSP90α-secreting M2-macrophages to exacerbate pancreatic ductal adenocarcinoma. J Hematol Oncol 2019;12:138. Anti-HSP90α antibodies could block the ligation of eHSP90α with its cell surface receptor CD91, thereby preventing the eHSP90α-induced feed-forward loop of eHSP90α expression and secretion. This finding is supported by our other recent studies. Octyl gallate (OG), a common antioxidant and preservative safely used in food additives and cosmetics, also showed inhibitory effects on EndoMT-derived CAFs and eHSP90α-induced macrophage M2-polarization and more HSP90α expression through blocking eHSP90α-TLR4 ligation.See Chua KV, Fan CS, Chen LL, Chen CC, Hsieh SC, Huang TS, Octyl gallate induces pancreatic ductal adenocarcinoma cell apoptosis and suppresses endothelial-mesenchymal transition-promoted M2-macrophages, HSP90α secretion, and tumor growth. Cell 2020;9(1):91.

[0005] Taken all together, eHSP90α is a potential therapeutic target for desmoplastic and M2-macrophage-driven cancers, and the development of anti-HSP90α antibodies may be a useful and promising strategy to target eHSP90α. Summary of the Invention

[0006] In one aspect, an isolated antibody is described herein, the isolated antibody comprising novel complementarity determining regions (CDRs) capable of specifically binding to an HSP90α epitope comprising the amino acid sequence EDK in the region of amino acids 235-244 and amino acids 251-260.

[0007] In some embodiments, the HSP90α can be eHSP90α.

[0008] In some embodiments, the isolated antibody may comprise heavy chain complementarity determining regions CDR1, CDR2 and CDR3 of the heavy chain variable region sequence of SEQ ID NO: 2 or SEQ ID NO: 12, and light chain complementarity determining regions CDR1, CDR2 and CDR3 of the light chain variable region sequence of SEQ ID NO: 7 or SEQ ID NO: 17.

[0009] In some embodiments, the heavy chain CDR1, CDR2 and CDR3 may be according to SEQ ID NO:2 and the light chain CDR1, CDR2 and CDR3 may be according to SEQ ID NO:7.

[0010] In some embodiments, the isolated antibody may comprise a heavy chain variable region that is at least 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%) identical to the sequence of SEQ ID NO:2 and a light chain variable region that is at least 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%) identical to the sequence of SEQ ID NO:7.

[0011] In some embodiments, heavy chain CDR1 may have the sequence of SEQ ID NO:3, heavy chain CDR2 may have the sequence of SEQ ID NO:4, heavy chain CDR3 may have the sequence of SEQ ID NO:5, light chain CDR1 may have the sequence of SEQ ID NO:8, light chain CDR2 may have the sequence of SEQ ID NO:9, and light chain CDR3 may have the sequence of SEQ ID NO:10.

[0012] In some embodiments, the heavy chain CDR1, CDR2 and CDR3 may be according to SEQ ID NO:12 and the light chain CDR1, CDR2 and CDR3 may be according to SEQ ID NO:17.

[0013] In some embodiments, the isolated antibody may comprise a heavy chain variable region that is at least 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%) identical to the sequence of SEQ ID NO:12 and a light chain variable region that is at least 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%) identical to the sequence of SEQ ID NO:17.

[0014] In some embodiments, heavy chain CDR1 may have the sequence of SEQ ID NO: 13, heavy chain CDR2 may have the sequence of SEQ ID NO: 14, heavy chain CDR3 may have the sequence of SEQ ID NO: 15, light chain CDR1 may have the sequence of SEQ ID NO: 18, light chain CDR2 may have the sequence of SEQ ID NO: 19, and light chain CDR3 may have the sequence of SEQ ID NO: 20.

[0015] In some embodiments, the isolated antibody may be an antibody comprising an Fc region, a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a single chain antibody, an scFV multimer, a monoclonal antibody, a monovalent antibody, a multispecific antibody, a humanized antibody or a chimeric antibody.

[0016] Also described herein are nucleic acid molecules comprising a nucleic acid sequence encoding the antibodies disclosed herein.

[0017] In some embodiments, provided herein is a host cell comprising the nucleic acid molecule.

[0018] Also described herein are pharmaceutical compositions comprising an antibody described herein or a nucleic acid molecule comprising a nucleic acid sequence encoding an antibody disclosed herein. The pharmaceutical composition may further comprise a pharma- ceutically acceptable carrier and / or other therapeutic agents (e.g., other anti-cancer agents, cytotoxic agents, or immunomodulatory agents). Examples of therapeutic agents include, but are not limited to, gemcitabine.

[0019] eHSP90α may be used as a therapeutic strategy against desmoplasia (particularly cancer desmoplasia), and thus, also described herein is a method of treating cancer desmoplasia in a subject, comprising administering a therapeutic agent that targets eHSP90α to a subject in need thereof.

[0020] In some embodiments, the antibodies described herein may also be used to inhibit cancer cell growth or cancer cell metastasis. Accordingly, described herein is a method of treating cancer in a subject, comprising administering to a subject in need thereof an effective amount of an antibody described herein or a nucleic acid molecule comprising a nucleic acid sequence encoding an antibody disclosed herein.

[0021] In some embodiments, the antibodies described herein may also be used to reduce or prevent the formation of fibrosis. Accordingly, described herein is a method of treating fibrosis in a subject, comprising administering to a subject in need thereof an effective amount of an antibody described herein or a nucleic acid molecule comprising a nucleic acid sequence encoding an antibody disclosed herein, wherein the fibrosis may be cancer fibrosis.

[0022] In some embodiments, the method may further include administering another therapeutic agent to the subject. The time for administering the therapeutic agent is not particularly limited. In some embodiments, the therapeutic agent may be administered at the same time as the antibody or nucleic acid molecule is administered. In some embodiments, the therapeutic agent may be administered after the antibody or nucleic acid molecule is administered.

[0023] In some embodiments, in a method of treating cancer or fibrosis in a subject, blood HSP90α levels in the subject can be detected using the isolated antibodies described herein to monitor tumor regression in the subject. In some embodiments, blood HSP90α levels in the subject can be blood HSP90α levels in the subject's whole blood or serum.

[0024] In some embodiments, the cancer may have desmoplastic characteristics.

[0025] In some embodiments, the cancer may have M2-macrophage-promoting characteristics.

[0026] Examples of cancer may include, but are not limited to, pancreatic cancer, colon cancer, breast cancer, liver cancer, or lung cancer.

[0027] Also provided herein is a method of assessing tumor regression in a subject, comprising obtaining a blood sample from the subject and determining the level of HSP90α in the blood sample, hi some embodiments, the blood sample may be whole blood or serum.

[0028] In some embodiments, a method for assessing tumor regression in a subject may comprise obtaining blood samples from the subject administered IgG and other blood samples from other subjects administered an antibody described herein or a nucleic acid molecule comprising a nucleic acid sequence encoding an antibody disclosed herein, and determining the level of HSP90α in the blood samples from the subjects administered IgG, an antibody or a nucleic acid molecule described herein. If the level of HSP90α in the blood samples from the subjects administered an antibody or a nucleic acid molecule disclosed herein is lower than the level of HSP90α in the blood samples from the subjects administered IgG, it indicates that the antibody or nucleic acid molecule described herein may effectively inhibit tumor growth or reduce tumor volume.

[0029] The details of one or more embodiments of the disclosure are set forth in the description below. Other features, objects, and advantages of the disclosure will be apparent from the description and the claims. [Brief description of the drawings]

[0030] [Figure 1]Figure 1 is a set of graphs showing the characterization of mouse anti-HSP90α monoclonal antibodies: (a) Western blot analysis of HSP90α binding capacity of culture supernatants of six hybridoma clones from mice immunized with rHSP90α; (b) ELISA of HSP90α binding activity of culture supernatants of six hybridoma clones; (c) Subtype characterization to identify both clone 2 and clone 6 antibodies as immunoglobulins of IgG2b isotype containing a kappa light chain; (d) Proximity ligation assay (PLA) of the level of physical association of CD91 with HSP90α and IKKα, respectively, in PANC-1 cells stimulated with 15 μg / ml rHSP90α in the absence or presence of 10 μg / ml control IgG or clone 2 or clone 6 anti-HSP90α antibodies. (e) Transwell invasion assay for the cell invasion ability of SW620, LoVo and BxPC-3 cells pretreated with PBS or 15 μg / ml rHSP90α for 16 hours. (f) Transwell invasion assay for the cell invasion ability of SW620 and PANC-1 cells prestimulated with 15 μg / ml rHSP90α plus 10 μg / ml control IgG or clone 2 or clone 6 anti-HSP90α antibody for 16 hours. (g) Cell spheroid formation assay for SW620, PANC-1 and Panc02 cells pretreated with 15 μg / ml rHSP90α plus 10 μg / ml control IgG or clone 2 or clone 6 anti-HSP90α antibody for 16 hours. [Diagram 2]Figure 2 is a set of graphs showing the characterization of humanized anti-HSP90α antibodies. (a) Assay of HSP90α binding kinetics of Clone 2-Chimera, Clone 2-hA, Clone 2-hB and Clone 2-hC anti-HSP90α antibodies using Biacore T200. (b) Equilibrium dissociation constant (KD) values ​​of Clone 2-Chimera, Clone 2-hA, Clone 2-hB and Clone 2-hC antibodies. Binding sensorgrams were generated using Biacore T200 and fitted to a simple 1:1 interaction model. (c) Transwell invasion assay of cell invasion ability of PANC-1 cells pretreated for 16 hours with 15 μg / ml rHSP90α plus 10 μg / ml control IgG or Clone 2-Chimera, Clone 2-hA, Clone 2-hB or Clone 2-hC anti-HSP90α antibodies. (d) Assay of cell spheroid formation ability of PANC-1 cells pretreated for 16 hours with 15 μg / ml rHSP90α plus 10 μg / ml control IgG or Clone 2-Chimera, Clone 2-hA, Clone 2-hB or Clone 2-hC anti-HSP90α antibodies. (e) Viability of ARPE-19 retinal pigment epithelial cells upon treatment with serial concentrations of 17-AAG and HH01 (i.e., Clone 2-hA) antibodies, respectively, for 72 hours. (f) Pharmacokinetics of HH01 antibody in male mice after intravenous (IV) injection at a single dose of 10 mg / kg. [Diagram 3]FIG. 3 is a set of graphs showing the epitope identification of Clone 2-chimera and HH01 (i.e., Clone 2-hA) anti-HSP90α antibodies. (a) Domain scanning assay to clarify which HSP90α region was involved in the binding with Clone 2 antibody. (b) Peptide scanning assay to examine which site in HSP90α was involved in the binding with Clone 2-chimera antibody. (c) Peptide scanning assay to examine which site in HSP90α was involved in the binding with HH01 antibody. (d) Alanine scanning assay to determine which aa residues in HSP90α were important for the binding with Clone 2-chimera and HH01 antibody. (e) Transwell invasion assay for cell invasion ability of PANC-1 cells pretreated with 15 μg / ml rHSP90α plus 15 μg / ml of control peptide (P-ctrl) or epitope-containing peptide (P-46) for 16 hours. (f) Assay of the cell spheroid formation ability of PANC-1 cells pretreated with 15 μg / ml rHSP90α plus 15 μg / ml of control peptide (P-ctrl) or epitope-containing peptide (P-46) for 16 h. [Figure 4]FIG. 4 is a set of graphs showing the evaluation of the prophylactic efficacy of HH01 antibody in a desmoplastic mouse PDAC model. (a) Masson's trichrome staining assay revealing tumor desmoplasia in EndoMT cell-associated Panc02 tumors, which was not observed in tumors derived from Panc02 cells alone. (b) Schematic diagram showing the prophylactic HH01 administration schedule in our desmoplastic mouse PDAC model. (c) Measurement of superficial tumor volume plotting tumor growth curves of EndoMT-associated Panc02 cell grafts from mice treated with control IgG and HH01 antibody, respectively. (d) Tumor weights obtained from mice sacrificed 30 days after inoculation. (e) Masson's trichrome staining of tumor tissue sections from mice treated with control IgG or HH01 antibody. (f) Serum HSP90α levels in mice subcutaneously inoculated with Panc02+EndoMT cell grafts and treated with control IgG or HH01 antibody. [Diagram 5] Figure 5 is a set of graphs showing the evaluation of therapeutic efficacy of HH01 antibody in a desmoplastic mouse PDAC model. (a) Schematic diagram showing therapeutic HH01 dosing schedule in our desmoplastic mouse PDAC model. (b) Measurement of superficial tumor volume plotting tumor growth curves of EndoMT-associated Panc02 cell grafts from mice treated with control IgG and HH01 antibody, respectively. (c) Tumor weights obtained from mice sacrificed 41 days after inoculation. (d) Masson's trichrome staining of tumor sections from mice treated with control IgG or HH01 antibody. (e) Serum HSP90α levels in mice subcutaneously inoculated with Panc02+EndoMT cell grafts and treated with control IgG or HH01 antibody. [Figure 6]Figure 6 is a set of graphs showing the evaluation of therapeutic efficacy of HH01 antibody in a desmoplastic humanized mouse PDAC model. (a) Schematic diagram showing therapeutic HH01 administration schedule in our desmoplastic humanized mouse PDAC model. (b) Measurement of superficial tumor volume plotting tumor growth curves of EndoMT-associated PANC-1 cell grafts from mice treated with control IgG, control IgG plus gemcitabine, and HH01 antibody plus gemcitabine, respectively. (c) Tumor weights obtained from mice sacrificed 39 days after inoculation. (d) Masson's trichrome staining of tumor sections from mice with different treatments. (e) Serum HSP90α levels in mice subcutaneously inoculated with PANC-1+EndoMT cell grafts and treated with control IgG, control IgG plus gemcitabine, or HH01 antibody plus gemcitabine. [Figure 7] Figure 7 is a set of graphs showing the evaluation of therapeutic efficacy of HH01 antibody in K-RasG12D-induced fibrogenic mouse PDAC model. (a) Schematic diagram showing therapeutic HH01 administration schedule in K-RasG12D-induced fibrogenic mouse PDAC model. (b) Kaplan-Meier survival curves of LSL-KrasG12D / Pdx1-Cre mice treated with control IgG and HH01 antibody, respectively. (c) Examples of pancreas and liver from LSL-KrasG12D / Pdx1-Cre mice treated with control IgG or HH01 antibody and their fibrogenesis levels. (d) Serum HSP90α levels of LSL-KrasG12D / Pdx1-Cre mice treated with control IgG or HH01 antibody. [Figure 8]FIG. 8 is a set of graphs showing eHSP90α-induced M2-type macrophages exhibiting significant tumor-promoting activity. (a and b) Promotion of tumor growth of Panc02 cell xenografts by rHSP90α-treated macrophages. Panc02 cells were subcutaneously injected into C57BL / 6 mice (n=6 per group) either alone or together with BMDMs pretreated with 100 ng / ml LPS or 15 μg / ml rHSP90α for 24 h. The size of the resulting tumors was measured superficially using a Vernier caliper and their volumes were calculated by the formula 1 / 2×length×width2 (a). Mice were sacrificed 28 days after inoculation and tumors were removed (b). @ P<0.01 when compared with "Panc02" or "Panc02+BMDM". (c) Immunohistochemical staining analysis of F4 / 80, CD163, CD4, and CD8 from tumors formed by Panc02 cells alone (designated as “Panc02” group) or Panc02 cells mixed with PBS-treated, LPS-treated, or rHSP90α-treated BMDM (designated as “Panc02+BMDM” group, “Panc02+LPS-treated BMDM” group, and “Panc02+rHSP90α-treated BMDM” group, respectively). H / E, hematoxylin and eosin staining. (d) DAPI-stained tissue sections of tumors derived from “Panc02”, “Panc02+BMDM”, “Panc02+LPS-treated BMDM”, and “Panc02+rHSP90α-treated BMDM” cell grafts. [Figure 9]FIG. 9 is a set of graphs showing the evaluation of therapeutic efficacy of HH01 antibody in M2-macrophage-driven mouse PDAC model. (a) Schematic diagram showing therapeutic HH01 administration schedule in our M2-macrophage-driven mouse PDAC model. (b) Measurement of superficial tumor volume plotting tumor growth curve of M2-macrophage-associated Panc02 cell grafts from mice treated with control IgG and HH01 antibody, respectively. (c) Tumor weight obtained from mice sacrificed 42 days after inoculation. (d) Serum HSP90α levels of mice subcutaneously inoculated with Panc02+M2-macrophage cell grafts and treated with control IgG or HH01 antibody. (e) Immunohistochemical staining analysis of CD163, CD204, CD4 and CD8 from tumors of mice treated with control IgG and HH01 antibody. H / E is hematoxylin and eosin staining. [Figure 10] FIG. 10 is a set of graphs showing immunohistofluorescence staining analysis of F4 / 80, iNOS, Arginase 1, CD4, CD8 and TNF-α from tumors of mice treated with control IgG and HH01 antibody. (a and b) An increase in F4 / 80+iNOS+ cells (indicated by arrows) and a decrease in F4 / 80+Arginase 1+ cells (indicated by arrows) were observed from tumor tissues of HH01-treated mice. (c) An increase in CD4+TNF-α+ cells (indicated by arrows) was observed from tumor tissues of HH01-treated mice. (d) An increase in CD8+TNF-α+ cells (indicated by white arrows) was observed from tumor tissues of HH01-treated mice. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0031] Described herein are novel antibodies that bind to HSP90α, such as eHSP90α.

[0032] The isolated antibody is 235 AEEKEDKEEE 244 and 251 ESEDKPEIED 260 The region may contain a novel CDR capable of specifically binding to an HSP90α epitope containing the amino acid sequence EDK.

[0033] The isolated antibody may comprise heavy chain complementarity determining regions CDR1, CDR2 and CDR3 of the heavy chain variable region sequence of SEQ ID NO:2 or SEQ ID NO:12 and light chain complementarity determining regions CDR1, CDR2 and CDR3 of the light chain variable region sequence of SEQ ID NO:7 or SEQ ID NO:17.

[0034] In one aspect, the heavy chain CDR1, CDR2 and CDR3 may be according to SEQ ID NO:2 and the light chain CDR1, CDR2 and CDR3 may be according to SEQ ID NO:7. In some embodiments, the isolated antibody may comprise a heavy chain variable region that is at least 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%) identical to the sequence of SEQ ID NO:2 and a light chain variable region that may be at least 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%) identical to the sequence of SEQ ID NO:7. In some embodiments, the heavy chain CDR1 may have the sequence of SEQ ID NO:3, the heavy chain CDR2 may have the sequence of SEQ ID NO:4, the heavy chain CDR3 may have the sequence of SEQ ID NO:5, the light chain CDR1 may have the sequence of SEQ ID NO:8, the light chain CDR2 may have the sequence of SEQ ID NO:9 and the light chain CDR3 may have the sequence of SEQ ID NO:10. In some embodiments, a nucleic acid molecule may also be provided that comprises a nucleic acid sequence encoding an antibody comprising a heavy chain variable region that is at least 80% identical to the sequence of SEQ ID NO: 2 and a light chain variable region that is at least 80% identical to the sequence of SEQ ID NO: 7. In some embodiments, the nucleic acid molecule may comprise a sequence that is at least 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%) identical to the sequence of SEQ ID NO: 1 for encoding the heavy chain variable region and a sequence that is at least 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%) identical to the sequence of SEQ ID NO: 6 for encoding the light chain variable region.

[0035] The sequences of SEQ ID NO:1 to SEQ ID NO:10 are listed in Table 1 below. Table 1: Clone 2 anti-HSP90α antibody [Table 1]

[0036] In one aspect, the heavy chain CDR1, CDR2 and CDR3 may be according to SEQ ID NO: 12 and the light chain CDR1, CDR2 and CDR3 may be according to SEQ ID NO: 17. In some embodiments, the isolated antibody may comprise a heavy chain variable region that is at least 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%) identical to the sequence of SEQ ID NO: 12 and a light chain variable region that may be at least 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%) identical to the sequence of SEQ ID NO: 17. In some embodiments, the heavy chain CDR1 may have the sequence of SEQ ID NO: 13, the heavy chain CDR2 may have the sequence of SEQ ID NO: 14, the heavy chain CDR3 may have the sequence of SEQ ID NO: 15, the light chain CDR1 may have the sequence of SEQ ID NO: 18, the light chain CDR2 may have the sequence of SEQ ID NO: 19 and the light chain CDR3 may have the sequence of SEQ ID NO: 20. In some embodiments, a nucleic acid molecule may also be provided that comprises a nucleic acid sequence encoding an antibody comprising a heavy chain variable region that is at least 80% identical to the sequence of SEQ ID NO: 12 and a light chain variable region that is at least 80% identical to the sequence of SEQ ID NO: 17. In some embodiments, the nucleic acid molecule may comprise a sequence that is at least 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%) identical to the sequence of SEQ ID NO: 11 for encoding the heavy chain variable region and a sequence that is at least 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%) identical to the sequence of SEQ ID NO: 16 for encoding the light chain variable region.

[0037] The sequences of SEQ ID NO:11 to SEQ ID NO:20 are listed in Table 2 below. Table 2: HH01 anti-HSP90α antibody [Table 2]

[0038] The antibody can specifically bind to HSP90α. More specifically, the antibody can bind to HSP90α with higher affinity than other non-HSP90α proteins. Furthermore, the CDRs of the heavy or light chain variable regions can be determined by any method known in the art.

[0039] The antibodies described herein exhibit high binding affinity to eHSP90α and therefore may inhibit desmoplasia within tumors to further suppress tumor growth or reduce tumor size.

[0040] Based on the antibody sequences and their CDRs disclosed herein, one skilled in the art may use any method known in the art to generate anti-HSP90α antibodies in various forms, which can specifically bind to an HSP90α epitope containing two EDK sites in the regions of amino acids 235-244 and 251-260.

[0041] Based on the sequence of the HSP90α epitope, synthetic peptides can competitively inhibit the tumor-promoting function of eHSP90α.

[0042] The term "antibody" as used herein includes various antibody structures having antigen-binding activity. For example, the antibody may include, but is not limited to, an antibody comprising an Fc region, a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a single chain antibody, a scFV multimer, a monoclonal antibody, a monovalent antibody, a multispecific antibody, a humanized antibody, or a chimeric antibody. In some embodiments, the antibody is a humanized antibody.

[0043] Also described herein are pharmaceutical compositions comprising the antibodies described herein. The pharmaceutical compositions include an isolated antibody described herein and a pharma- ceutical acceptable carrier.

[0044] Also described herein is a pharmaceutical composition comprising a nucleic acid molecule capable of encoding an antibody described herein. The pharmaceutical composition comprises a nucleic acid molecule capable of encoding an antibody described herein and a pharma- ceutical acceptable carrier.

[0045] The term "pharmaceutical acceptable carrier" means that the carrier should be compatible with the active ingredient (e.g., be able to stabilize the antibody) and should not be harmful to the subject being treated. The carrier can be at least one selected from the group consisting of active agents, adjuvants, dispersants, wetting agents and suspending agents. Examples of the carrier can be, but are not limited to, microcrystalline cellulose, mannitol, glucose, skimmed milk powder, polyethylene, polyvinylpyrrolidone, starch or combinations thereof.

[0046] The antibody, nucleic acid molecule, or pharmaceutical composition comprising one or more thereof may be administered to a subject orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, or via an implanted reservoir. As used herein, the term "parenteral" includes subcutaneous, intradermal, intravenous, intramuscular, intra-articular, intra-arterial, intrasynovial, intrasternal, intrathecal, intralesional, and intracranial injection or infusion techniques.

[0047] Also described herein is the use of an antibody or nucleic acid molecule for the manufacture of a medicament for treating cancer.

[0048] Also described herein are methods of treating cancer in a subject, comprising administering to the subject an effective amount of an antibody or nucleic acid molecule described herein.

[0049] Examples of cancers may include, but are not limited to, bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, leukemia, liver cancer, lymphoma, kidney cancer, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer including basal cell carcinoma, squamous cell carcinoma and melanoma, small intestine cancer, stomach cancer, thymus cancer and thyroid cancer. In some embodiments, the cancer has characteristics of desmoplasia, and in particular, desmoplasia may be found within or around tumor cells. In some embodiments, the cancer may be pancreatic cancer, colon cancer, breast cancer, liver cancer or lung cancer.

[0050] The antibodies described herein can inhibit cancer desmoplasia, immunosuppression, growth and metastasis.

[0051] The term "subject" refers to a human or non-human animal.

[0052] The terms "treating," "treat," or "treatment" refer to the application or administration of an antibody, nucleic acid molecule, or pharmaceutical composition to a subject with the intent to cure, alleviate, ameliorate, alter, modify, ameliorate, or affect a disease, condition, or predisposition. An "effective amount" refers to the amount of antibody or nucleic acid molecule necessary to confer the desired effect on the subject. As will be recognized by one of skill in the art, effective amounts will vary depending on the route of administration, excipient usage, and the possibility of co-administration with other therapeutic treatments, such as the use of other active agents.

[0053] The details of one or more embodiments of the disclosure are set forth in the description below. Other features, objects, and advantages of the disclosure will be apparent from the description and the claims. EXAMPLES

[0054] Without further elaboration, it is believed that one skilled in the art can, based on the above description, utilize the present disclosure to its fullest extent. Accordingly, the following specific examples are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way. All publications cited herein are incorporated by reference in their entirety.

[0055] Materials and Methods cell culture The human PDAC cell line PANC-1 was cultured in 10% fetal bovine serum (FBS) and 100 units / ml penicillin, 100 μg / ml streptomycin, and 2 mM LThe cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with a mixture of 1x PSG-glutamine in a humidified incubator at 37°C and 5% CO2. The human PDAC cell line BxPC-3, human CRC cell line SW620, and mouse PDAC cell line Panc02 were incubated in RPMI-1640 medium supplemented with 10% FBS and 1x PSG at 37°C in an atmosphere of 5% CO2 and 95% air. Under the same growth conditions, the human CRC cell line LoVo was maintained in Ham's F-12 medium containing 20% ​​FBS and 1x PSG, and the human retinal pigment epithelial cell line ARPE-19 (ATCC CRL-2302™; American Type Culture Collection, Manassas, VA, USA) was cultured in ATCC-formulated DMEM:F12 medium (cat.#30-2006, ATCC) supplemented with 10% FBS and 1x PSG. Human umbilical vein endothelial cells (HUVECs) were isolated and grown in M199 medium containing 20% ​​FBS, 100 units / ml penicillin, 100 μg / ml streptomycin, and 30 μg / ml endothelial cell growth supplement (EMD Millipore, Billerica, MA, USA) in a humidified incubator at 37°C and 5% CO2. See Fan CS, Chen LL, Hsu TA, et al. Endothelial-mesenchymal transition harnesses HSP90α-secreting M2-macrophages to exacerbate pancreatic ductal adenocarcinoma. J Hematol Oncol 2019;12:138. For EndoMT induction, HUVECs were preincubated with M199 medium containing 2% FBS for 16 hours, and then 0.3 μg / ml OPN was added and incubated for an additional 24 hours. Mouse endothelial cell line 3B-11 (ATCC CRL-2160™) was grown in RPMI-1640 medium supplemented with 10% FBS and 1×PSG. For EndoMT induction, 3B-11 cells were treated similarly to HUVECs, except that RPMI-1640 medium containing 1% FBS was used instead.Murine bone marrow-derived macrophages (BMDMs) were prepared as previously described and cultured in DMEM supplemented with 10% FBS and 1x PSG.See Fan CS, Chen LL, Hsu TA, et al. Endothelial-mesenchymal transition harnesses HSP90α-secreting M2-macrophages to exacerbate pancreatic ductal adenocarcinoma. J Hematol Oncol 2019;12:138.

[0056] Mouse model Mouse experiments were performed with permission from the Institutional Animal Care and Use Committee of the National Health Research Institutes (NHRI-IACUC-106031-A, 109022-M2-S02, and 109196-A). To establish the desmoplastic tumor transplantation model, 12-week-old C57BL / 6 mice were subcutaneously inoculated with a mixture of Panc02 cells and EndoMT-derived CAFs (i.e., OPN-treated 3B-11 cells). See Fan CS, Chen LL, Hsu TA, et al. Endothelial-mesenchymal transition harnesses HSP90α-secreting M2-macrophages to exacerbate pancreatic ductal adenocarcinoma. J Hematol Oncol 2019;12:138 and Chua KV, Fan CS, Chen LL, Chen CC, Hsieh SC, Huang TS, Octyl gallate induces pancreatic ductal adenocarcinoma cell apoptosis and suppresses endothelial-mesenchymal transition-promoted M2-macrophages, HSP90α secretion, and tumor growth. Cells 2020;9(1):91. Further mouse treatments and schedules were as indicated in the figures and associated text. The size of the developing tumors was measured superficially with a Vernier caliper and tumor volumes were calculated as 1 / 2 × length × width. 2 The tumor mass was calculated using the formula: When the mice were sacrificed, the actual tumor mass was measured. To establish a desmoplastic tumor transplantation model in humanized mice, human hematopoietic stem cell (hHSC)-transplanted NOD-SCID IL2R null A mixture of PANC-1 cells and OPN-treated HUVECs was subcutaneously inoculated into hHSC-engrafted ASID mice. The employed hHSC-engrafted ASID mice were produced at the National Laboratory Animal Center (Taipei, Taiwan), and both of them expressed human CD45+ / - 38% of total lymphocytes. +The results included the cellular level. To establish the M2-macrophage-promoting mouse PDAC model, C57BL / 6 mice were subcutaneously inoculated with a mixture of Panc02 cells and rHSP90α-treated BMDM. Further mouse treatments and schedules were as shown in the figures and related text. Furthermore, LSL-KrasG12D / Pdx1-Cre transgenic mice were employed as a spontaneous PDAC-developing mouse model to evaluate the therapeutic efficacy of HH01 antibody. LSL-KrasG12D and Pdx1-Cre breeder mice were obtained from the Mouse Models of Human Cancers Consortium Repository of the National Cancer Institute (Frederick, MD, USA). LSL-KrasG12D mice were crossed with Pdx1-Cre mice to generate LSL-KrasG12D / Pdx1-Cre mice. Further mouse treatments were performed as shown in the figures and related text.

[0057] Western blot analysis Mouse hybridomas were generated from mice immunized with recombinant full-length human HSP90α (rHSP90α; PeproTech, Cranberry, NJ, USA) of 732 amino acids (aa) according to conventional protocols. Yokoyama WM, Production of monoclonal antibody supernatant and ascites fluid. Curr Protoc Mol Biol 2008;83:11.10.1-11.10.10. The hybridomas were then preliminarily screened by adopting a general procedure of Western blot analysis. Fan CS, Chen LL, Hsu TA, et al. Endothelial-mesenchymal transition harnesses HSP90α-secreting M2-macrophages to exacerbate pancreatic ductal adenocarcinoma. J Hematol Oncol 2019;12:138. Hybridoma culture media was collected and reacted with membrane strips containing HSP90α and molecular weight marker proteins blotted from electrophoretic SDS-polyacrylamide gels. After two washes with PBS plus 0.05% Tween-20 (PBST), the membrane strips were incubated with horseradish peroxidase-conjugated secondary antibodies for 1 h. Immunoreactive protein bands were visible after three washes with PBST followed by reaction with 0.3 mg / ml 3,3',5,5'-tetramethylbenzidine (Sigma-Aldrich, St. Louis, MO, USA) in 0.015% H2O2.

[0058] Enzyme-linked immunosorbent assay (ELISA) To assay the HSP90α binding activity of the prepared antibodies, 96-well plates were coated with 12.5 ng / ml rHSP90α in capture buffer (BioLegend, San Diego, CA, USA) by overnight incubation at 4°C. The coated plates were washed twice with PBST and blocked with PBST plus 3% bovine serum albumin (BSA). The prepared antibodies were added and incubated for 2 h at room temperature. After washing three times with PBST, horseradish peroxidase-conjugated secondary antibodies were added and incubated for an additional 1 h at 37°C. After three washes, 0.3 mg / ml 3,3',5,5'-tetramethylbenzidine in 0.015% H2O2 was added to each well and incubated for 10 min at room temperature in the dark. The reaction was stopped by the addition of 0.5 M H2SO4 and the OD 450 The values ​​were measured by an Infinite M200 microplate reader (TECAN, Männedorf, Switzerland). Furthermore, characterization of the immunoglobulin (IgG) isotype of the anti-HSP90α antibodies was performed by using the Mouse Ig Isotyping ELISA Ready-Set-Go!™ Kit (eBioscience™, Thermo Fisher Scientific, Waltham, MA, USA). The ELISA protocol was also used to assay secreted HSP90α levels in mouse serum samples as previously described. Chen JS, Hsu YM, Chen CC, Chen LL, Lee CC, Huang TS, Secreted heat shock protein 90α induces colorectal cancer cell invasion through CD91 / LRP-1 and NF-κB-mediated integrin α. V expression. J Biol Chem 2010;285(33):25458-66.

[0059] Proximity Ligation Assay (PLA) On glass coverslips, 2 x 10 cells per 22 x 22 mm coverslip 5 PANC-1 cells seeded at a density of 1000 cells were incubated in 0.5% serum-containing medium at 37°C and 5% CO2 in a humidified atmosphere for 16 h. Cells were then supplemented with PBS or 15 μg / ml rHSP90α in the absence or presence of 10 μg / ml control IgG or anti-HSP90α antibodies to be tested and incubated for a further 24 h. Treated cells were then fixed with 3% paraformaldehyde and blocked with the blocking solution provided in the Duolink in situ PLA kit (Olink Bioscience, Uppsala, Sweden). Furthermore, cell samples were incubated overnight at 4°C with anti-CD91 antibody (1:80, cat.#550495, BD Biosciences, San Jose, CA, USA) mixed with anti-HSP90α antibody (1:80, cat.#AHP-1339, AbD Serotec, Raleigh, NC, USA) or anti-IKKα antibody (1:80, cat.#3285, Epitomics, Burlingame, CA, USA). After washing twice with Tris-buffered saline plus 0.05% Tween 20, cell samples were incubated with PLA probes for the subsequent ligation and amplification steps according to the manufacturer's instructions for the Duolink in situ PLA kit. Finally, nuclei were counterstained with 4',6'-diamidino-2-phenylindole (DAPI, Sigma-Aldrich). Images were captured and analyzed using a Leica TCS SP5II confocal microscope and LAS AF Lite 4.0 software (Leica, Wetzlar, Germany).

[0060] Transwell invasion assay Cancer cells were serum starved for 16 h in 0.5% FBS-containing medium in a humidified incubator at 37° C. and 5% CO2, and then PBS or 15 μg / ml rHSP90α was added in the absence or presence of 10 μg / ml control IgG or the anti-HSP90α antibody to be tested. After an additional 24 h, treated cells were harvested as aliquots (1×10 cells per aliquot) in culture medium containing 0.5% FBS. 5 1000 cells) and each aliquot was seeded into the upper chamber of a transwell insert pre-coated with 5-fold diluted Matrigel (BD Biosciences). Cells were allowed to invade through the Matrigel into the bottom chamber containing culture medium plus 10% FBS for 16 h. The transwell insert filters were then fixed and stained with Giemsa. The invaded cells under the filter were photographed using an Axiovert S100 / AxioCam HR microscope system (Carl Zeiss, Oberkochen, Germany) and further quantified by Image-Pro Plus software (Media Cybernetics, Silver Spring, MD, USA).

[0061] Cell spheroid formation assay (cell self-renewal activity assay) 1000 cancer cells were seeded in each well of a 24-well plate precoated with a 4 mm thick layer of 0.5% agarose. After 24 h of incubation in serum-free medium at 37 °C and a humidified atmosphere of 5% CO2, the cells were supplemented with PBS or 15 μg / ml rHSP90α in the absence or presence of 10 μg / ml control IgG or anti-HSP90α antibodies to be tested. The incubation was maintained for 10-14 days by supplementation of fresh serum-free medium every 3 days. Finally, cell spheroids, characterized by attached, non-attached, and diameters larger than 100 μm, were photographed and counted under an Olympus IX71 inverted microscope (Center Valley, PA, USA). The % spheroid formation was calculated by the formula: (number of cell spheroids / 1000) × 100%.

[0062] Cloning and sequencing of mouse antibody genes from hybridoma cells Total RNA was isolated from anti-HSP90α IgG-producing mouse hybridoma cells and converted to cDNA by reverse transcriptase plus random hexamers. Mouse Ig-Primer Set (Sigma-Aldrich) was used to prime the variable domains of the IgG heavy (H) and light (L) chains (i.e., V H and V L The PCR product was cloned into the pJET1.2 / blunt cloning vector provided in the CloneJET PCR cloning kit (Thermo Fisher Scientific), followed by clone selection and DNA sequence analysis.

[0063] Construction and expression of recombinant antibodies IgG V H and V L The cDNA sequences of the H and L chain constant domains (i.e., C H and C L The DNA was inserted into the site immediately before the region encoding the V H The cDNA was inserted into the EcoRI-NheI site following the human IL-2 signal sequence to express a recombinant protein containing an Fc fragment with mutations at residues Q250T, E356D, M358L and L428M. LThe cDNA of the domain was inserted into pFUSE2ss-CLIg-hk plasmid after digestion with EcoRI and BsiWI. The recombinant DNA sequences encoding the recombinant IgG H and L chains were further amplified using hIgHG-F / hIgHG-R and CLIg-F / CLIg-R primers and inserted into pcDNA3.4-TOPO plasmid (Thermo Fisher Scientific), respectively. Finally, ExpiCHO cells were co-transfected with the recombinant pcDNA3.4-TOPO plasmids encoding the H and L chains in a 2:3 ratio. The medium of the transfected ExpiCHO cells was harvested after 8-10 days of culture. The recombinant antibodies were purified by Protein A column in the Gibco™ ExpiCHO™ Expression System (Thermo Fisher Scientific).

[0064] Antibody Humanization and Optimization The F(ab')2 region of a mouse monoclonal antibody was humanized using computational methods, and all calculations were performed with Discovery Studio 2018 software (BIOVI, San Diego, CA, USA). Complementarity determining regions (CDRs) were identified using published methods. See Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C, Sequences of proteins of immunological interest. USDepartment of Health and Human Services, NIH, Bethesda, MD, 1991. L and V HThe three-dimensional (3D) structures of the domains were modeled by the X-ray templates of PdbID: 4X0K and PdbID: 4Y5X, respectively. Johnson JL, Entzminger KC, Hyun J, Kalyoncu S, Heaner DP, Morales Jr IA, Sheppard A, Gumbart JC, Maynard JA, Lieberman RL, Structural and biophysical characterization of an epitope-specific engineered Fab fragment and complexation with membrane proteins: implications for co-crystallization.Acta Crystallogr D Biol Crystallogr 2015;71:896-906 and Moraga I, Wernig G, Wilmes S, Gryshkova V, Richter CP, Hong WJ, Sinha R, Guo F, Fabionar H, Wehrman TS, Krutzik P, Demharter S, Plo I, Weissman IL, Minary Majeti PR, Constantinescu SN, Piehler J, Garcia KC, Tuning. cytokine receptor signaling by re-orienting dimer See Cell 2015;160:1196-1208. For further 3D structure calculations, the CDRs of the mouse antibody were grafted into an in-house human template. With regard to suggesting mutations that would improve the recombinant antibody, the calculations included aggregation, post-translational modifications, protease cleavage, pharmacokinetics and stability aspects.

[0065] HSP90α binding affinity assay To measure the HSP90α binding properties of anti-HSP90α antibodies, binding kinetics assays were performed using a Biacore T200 (Cytiva, Marlborough, MA, USA). Anti-HSP90α antibodies of interest were applied as ligands to a Protein A Series S sensor chip to reach approximately 3000–5000 response units. A series of concentrations of rHSP90α (1.5625–100 nM) in HBS-EP+ buffer were injected across the chip surface. Binding was monitored for 60 s, with a final dissociation time of 1500 s.

[0066] Retinal cytotoxicity assay ARPE-19 cells were seeded onto 96-well plates at a density of 4000 cells per well and treated with various concentrations of 17-AAG or anti-HSP90α antibody HH01 in triplicate for 72 h. OD was measured using a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS; Sigma-Aldrich) assay. 490 was measured to assess cell viability in each treatment.

[0067] Pharmacokinetic assays The pharmacokinetic profile of anti-HSP90α antibody HH01 was investigated in Bltw:CD1(ICR) male mice (BioLASCO Taiwan, Taipei, Taiwan). Mice (n=5) weighing 25-30 g per mouse were intravenously injected with 10 mg / kg HH01 antibody. Food and water were always available ad libitum. For determination of serum exposure levels of HH01 antibody, blood samples were collected at 0.04, 0.08, 0.25, 1, 2, 3, 7, 9, 14, 16, 18, 21, 23, 25, 35, 42, 49, 56, and 63 days after administration. For these samples, human IgG1 levels were further measured by ELISA kit (Cayman Chemical, Michigan, USA) to represent the remaining HH01 levels in mouse serum.

[0068] Cloning, expression and purification of full-length and truncated HSP90α Full-length HSP90α (aa1-732) and its three truncated fragments including the N-terminal plus linker domain (aa1-272), the N-terminal to middle domain (aa1-629) and the C-terminal domain (aa630-732) were cloned, expressed and purified. Briefly, each cDNA sequence with an 8xHis tag was amplified by PCR from the human ORF clone (NM_005348) with primers containing XhoI and BamHI sites. The PCR products were purified, digested with restriction enzymes and inserted into pET-23a plasmid (Sigma-Aldrich). The recombinant plasmids were then transformed into Escherichia coli ClearColi® competent cells (Lucigen, Middleton, WI, USA) and expression of the recombinant constructs was stimulated by the addition of isopropyl-D-thiogalacto-pyranoside. The expressed histidine-tagged full-length and truncated HSP90α were further purified by using a Ni-NTA column (Qiagen, Germantown, MD, USA) according to the manufacturer's instructions. The purified proteins were finally dialyzed against a storage buffer consisting of 25 mM Tris-HCl (pH 7.0), 50 mM NaCl, 0.1% TritonX-100, 50% glycerol, 1 mM EDTA, and 1 mM DTT, and the protein concentration was determined by Bradford protein assay (Bio-Rad Laboratories, Hercules, USA).

[0069] Epitope determination First, a domain scanning strategy was used to roughly define the HSP90α region involved in binding with our prepared antibody. The above full-length HSP90α and its three truncated fragments were employed to coat a 96-well ELISA plate to assay the binding activity of the mouse monoclonal antibody to be tested. The results suggested that the mouse monoclonal antibody to be tested binds to the aa1-272 region of HSP90α. Therefore, in the peptide scanning strategy, a library of 132 peptides consisting of a series of 10-aa peptides offset by two aa to span the sequence of the aa21-272 region of HSP90α was synthesized by Mimotopes Pty Ltd (Melbourne, Victoria, Australia). This series of peptides was used to coat a 96-well ELISA plate to assay the binding activity of the antibody to be tested. Based on the sequences suggested by the peptide scanning results, an alanine scanning strategy was further employed to examine which aa residues were important for the binding of the antibody to be tested. The results of the peptide scanning assay identified HSP90α as the epitope that binds to the antibody being tested. 235 AEEKEDKEEE 244 and 251 ESEDKPEIED 260 Therefore, 19 peptides were synthesized with each aa replaced by alanine sequentially (Genozyme Biotech Co., Taipei, Taiwan). These peptides were subjected to ELISA as described above.

[0070] Masson's trichrome staining Paraffin-embedded mouse tissue sections were deparaffinized with xylene and rehydrated through a series of ethanol dilutions. Masson's trichrome staining was performed using a Trichrome Stain Kit (ScyTek Laboratories, Utah, USA) according to the manufacturer's protocol. Stained sections were dehydrated in graded ethanol solutions and xylene, and finally mounted in mounting solution overnight at room temperature in the dark. Sections were observed and photographed using an Axiovert S100 / AxioCam HR microscope system.

[0071] Immunohistochemical staining Mouse tissue sections with a thickness of 4 μm were deparaffinized with xylene and rehydrated in graded ethanol dilutions. Antigen retrieval was performed by heating the sections under high pressure in 10 mM citrate buffer at pH 6.0 for 15 min. Endogenous peroxidase activity was blocked with 0.3% H2O2. Before staining, the sections were blocked with 3% BSA in PBS in a humidified chamber at room temperature for 30 min. Then, anti-F4 / 80 antibody (1:100, cat.#MCA497R, AbD Serotec), anti-CD163 antibody (1:80, cat.#sc-33560, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-CD204 antibody (1:100, cat.#GTX51749, GeneTex, Hsinchu, Taiwan), anti-CD4 antibody (1:100, cat.#GTX44531, GeneTex) or anti-CD8 antibody (1:100, cat.#GTX16696, GeneTex) were added and incubated overnight at 4°C. After washing, secondary antibody was added and incubated at room temperature for 30 minutes. Sections were further detected using the DAKO REAL EnVision Detection System (DK-2600, Produktionsvej 42, Glostrup, Denmark) and counterstained with hematoxylin. Stained sections were dehydrated, mounted with mounting solution, and finally observed and photographed using an Axiovert S100 / AxioCam HR microscope system.

[0072] Immunohistofluorescence staining Mouse tissue sections were deparaffinized, rehydrated, and antigen retrieved as described above. Sections were blocked with 5% BSA in PBS for 30 min at room temperature in a humidified chamber. Three antibody sets were then added and incubated overnight at 4°C, respectively. Antibody set 1 consisted of anti-F4 / 80 antibody (1:100, cat.#MCA497R, AbD Serotec), anti-iNOS antibody (1:100, cat.#GTX15323, GeneTex), and anti-Arginase I antibody (1:50, cat.#sc-271430, Santa Cruz Biotechnology). Antibody set 2 included anti-CD4 antibody (1:100, cat.#GTX44531, GeneTex) and anti-TNF-α antibody (1:75, cat.#sc-52746, Santa Cruz Biotechnology). Antibody set 3 consisted of anti-CD8 antibody (1:100, cat.#GTX16696, GeneTex) and anti-TNF-α antibody (1:75, cat.#sc-52746, Santa Cruz Biotechnology). After washing, the respective fluorescently labeled secondary antibodies were added and incubated for another hour at room temperature. Nuclei were stained with DAPI. Finally, sections were observed, photographed and analyzed using a Leica TCS SP5 II confocal microscope and LAS AF Lite4.0 software.

[0073] result Preparation and characterization of mouse anti-HSP90α monoclonal antibody Six hybridoma clones were derived from mice immunized with recombinant human HSP90α (rHSP90α). Their culture supernatants were harvested to assay binding activity to HSP90α using standard Western blotting and ELISA protocols. Antibodies produced by these hybridomas, except for clone 5, were shown to bind to the antigen rHSP90α (Figure 1(a)). The binding activity was further quantified by ELISA, and clones 2 and 6 showed the top two HSP90α binding levels and were therefore selected for the next assay (Figure 1(b)). Antibodies from the two clones were purified and both were identified as immunoglobulins of IgG2b isotype containing a kappa light chain (Figure 1(c)). They efficiently blocked the binding of eHSP90α to its cell surface receptor CD91 and to IKKα downstream of CD91 (Figure 1(d)). A given eHSP90α exerts its cancer-promoting effects through multiple mechanisms, such as induction of cancer cell EMT, migration, invasion, and stemness acquisition. Consistent with previous studies, our transwell invasion assay revealed that rHSP90α acted as a potent inducer of cancer cell invasiveness (Fig. 1(e)), and rHSP90α-induced cancer cell invasion could be dramatically abolished by clone 2 and clone 6 anti-HSP90α antibodies (Fig. 1(f)). Furthermore, rHSP90α-induced cancer cell stemness acquisition, reflected by increased spheroid formation activity, could also be significantly inhibited by clone 2 and clone 6 antibodies (Fig. 1(g)). Taken together, our data suggested that anti-HSP90α monoclonal antibodies could potentially be developed and used to address eHSP90α-promoted malignancies.

[0074] Humanization of Clone 2 anti-HSP90α antibody Next, we analyzed the IgG variable domains of the heavy and light chains of the anti-HSP90α antibodies, clone 2 and clone 6 (i.e., V H and V L The cDNA sequences of V and VL were cloned and analyzed, respectively. The cDNA sequences and the encoded amino acid residues are listed in Tables 1 and 2 above. Clone 2 was further selected for humanization. Hand V L The DNA sequence of the human IgG constant domains of H and L chains (i.e., C H and C L ) just before the region expressing rHSP90α, and expressed a recombinant IgG1 antibody called "Clone 2-chimera". Furthermore, we constructed three mutants of Clone 2-chimera, designated as Clone 2-hA, Clone 2-hB and Clone 2-hC, with the aim of improving the properties of the antibody in terms of aggregation, protease cleavage, post-translational modification, pharmacokinetics and stability according to the suggestions and calculations of computer-aided structural modeling. The mutation sites are listed in Table 3 below. These engineered humanized recombinant antibodies were expressed by ExpiCHO cells and analyzed for HSP90α binding affinity after purification. Kinetic assays were performed using Biacore T200 to determine the binding properties of Clone 2-chimera, Clone 2-hA, Clone 2-hB and Clone 2-hC antibodies to rHSP90α (Figure 2(a)). The equilibrium dissociation constants (K D ) values ​​are 0.94×10 -10 , 1.87×10 -10 , 1.48×10 -10 and 1.47 x 10 -10 M was further calculated (FIG. 2(b)), suggesting that the mutations in the clone 2-hA, clone 2-hB, and clone 2-hC antibodies did not significantly reduce the HSP90α binding affinity of the clone 2-chimera. [Table 3]

[0075] To preliminarily evaluate the anti-cancer efficacy of these humanized anti-HSP90α antibodies, we assayed their inhibitory activity against rHSP90α-induced PDAC cell invasion and spheroid formation. The results of the transwell invasion assay showed that clone 2-chimera and clone 2-hA were superior to clone 2-hB, clone 2-hC and their parent clone 2 in suppressing rHSP90α-induced invasiveness of human PDAC PANC-1 cells (Figure 2(c)). In the spheroid formation assay, clone 2-hA further showed the most superior efficacy in suppressing rHSP90α-induced spheroid formation of PANC-1 cells (Figure 2(d)). Therefore, clone 2-hA was finally selected for further in vitro and in vivo assays and was named HH01 antibody. The solubility of HH01 antibody in PBS was higher than 10 mg / ml, and Dynamic Light Scattering assay revealed that HH01 antibody had a size of 19.33 nm mean diameter with a range of 10-50 nm (not shown), suggesting that HH01 antibody is not likely to form aggregates. Considering that the clinical use of small molecule HSP90 inhibitors including geldanamycin and resorcinol derivatives causes retinal photoreceptor cell damage when they accumulate in the retina to a certain level, we further evaluated whether HH01 antibody exhibits toxicity in non-cancerous retinal cells by examining the effect of HH01 antibody on the viability of ARPE-19 retinal pigment epithelial cells. As shown in Figure 2(e), 17-AAG had an IC of 64.7 nM against ARPE-19 cells. 50 On the other hand, the HH01 antibody did not cause obvious cytotoxicity in ARPE-19 cells even when its concentration reached 594.3 nM (100 μg / ml). Furthermore, the pharmacokinetics of the HH01 antibody was investigated in male mice, which showed that the HH01 antibody was induced in mouse blood at a concentration of 3 × 10 -3 The clearance rate in ml / min / kg and the half-life (T 1 / 2 ) (Fig. 2(f)). 1 / 2The results showing high serum exposure levels as well as results after intravenous dosing demonstrated that the HH01 antibody is suitable for further development.

[0076] Identification of the epitope of the HH01 antibody As listed in Table 3 above, the HH01 antibody has a novel amino acid (aa) sequence in the complementarity determining region (CDR) and can specifically bind to human HSP90α, therefore, we intended to identify which region of HSP90α is bound by the HH01 antibody. In a preliminary study, we adopted a strategy of HSP90α domain scanning to clarify the HSP90α region involved in binding with the clone 2 antibody. Full-length HSP90α (aa1-732) and its three truncated fragments including the N-terminus plus linker domain (aa1-272), the N-terminus to middle domain (aa1-629) and the C-terminus domain (aa630-732) were cloned, expressed and purified. The binding activity of the clone 2 antibody to the full-length and truncated HSP90α was then assayed by conventional ELISA. The results showed that the clone 2 antibody bound to the aa1-272 region and the full-length protein (Figure 3(a)), suggesting that the binding epitope of the clone 2 antibody could be within the N-terminus and linker domain (aa1-272) of HSP90α. Furthermore, a peptide scanning strategy was adopted to clarify the binding epitopes of the clone 2-chimera and HH01 antibodies. A peptide library was established consisting of a series of 10-aa peptides with an 8-aa overlap between any two consecutive peptides, and the sequence of the aa21-272 region of HSP90α was scanned. The binding activity of the clone 2-chimera and HH01 antibodies against this series of 10-aa peptides was assayed by ELISA. The results showed that the potential epitope site of the clone 2-chimera antibody was within the N-terminus and linker domain (aa1-272) of HSP90α. 235 AEEKEDKEEE 244 and 251 ESEDKPEIED 260We found that the two sites were involved in the binding of HH01 antibody (Fig. 3(b)). Consistently, these two sites could also act as binding epitopes for HH01 antibody (Fig. 3(c)). Based on the sequences of these two sites, we synthesized two series of 10-aa peptides in which the aa residues were sequentially replaced with alanine. We adopted an alanine scanning strategy to investigate the aa residues important for the binding of clone 2-chimera and HH01 antibody to the epitope sites. The results showed that the replacement of E237, E239, K241, E253 and K255 with alanine dramatically reduced the binding activity of clone 2-chimera antibody to the epitope site (Fig. 3(d)). In addition, another D240 was also involved in the binding of HH01 antibody (Fig. 3(d)). Based on the above epitope mapping results, we synthesized a peptide with the sequence of the aa227-272 region of HSP90α. This peptide competitively inhibited rHSP90α-induced PANC-1 cell invasion (Figure 3(e)) and spheroid formation (Figure 3(f)), supporting the idea that the HSP90α region containing the epitope site could be targeted for novel anticancer strategies.

[0077] Evaluation of the prophylactic and therapeutic efficacy of HH01 antibody in a desmoplastic mouse PDAC transplant model The HH01 antibody was of further in vivo anti-cancer assays. In our previous study, EndoMT-derived CAFs significantly promoted tumor growth of pancreatic adenocarcinoma Panc02 cell xenografts. Our results of Masson's trichrome staining further revealed that EndoMT cell-associated Panc02 tumors showed significant levels of desmoplasia that were not observed in tumors derived from Panc02 cells alone (Figure 4(a)). To investigate the in vivo anti-cancer activity of the HH01 antibody, we assayed its cancer prevention activity in the EndoMT-associated mouse PDAC model following the previous schedule with the mouse antibody. C57BL / 6 mice were subcutaneously inoculated with Panc02 cells plus EndoMT cells. Four days after inoculation, the mice were further intravenously administered 5 mg / kg per dose of control IgG or HH01 antibody for eight doses at 3-day intervals (Figure 4(b)). As shown in Figure 4(c), the kinetics of tumor growth of EndoMT-associated Panc02 cell grafts was potently inhibited by HH01 antibody. All mice were sacrificed 30 days after inoculation, and their tumors were removed for weight measurement. As expected, HH01 treatment significantly suppressed the tumor size of Panc02+EndoMT cell grafts (p<0.001, Figure 4(d)). Tumor desmoplasia was also significantly prevented by HH01 treatment (Figure 4(e)). Furthermore, elevated eHSP90α levels were detected in the serum of our desmoplasia mouse PDAC model, and serum HSP90α levels were significantly reduced upon HH01 treatment in mice (Figure 4(f)). These data suggest that HH01 antibody is a potent agent to prevent EndoMT-promoted tumor growth of PDAC cells.

[0078] To evaluate the therapeutic efficacy of the HH01 antibody in a desmoplastic murine PDAC model, C57BL / 6 mice were inoculated subcutaneously with Panc02+EndoMT cell grafts. Twenty days after inoculation, mice were cultured at 75 mm 3Mice bearing tumors with an average size of 1000 μg / mL were intravenously infused with either control IgG or HH01 antibody at 5 mg / kg per dose for three doses at 7-day intervals (Figure 5(a)). The results showed that HH01 treatment completely suppressed the tumor growth kinetics of Panc02+EndoMT cell grafts (Figure 5(b)). Tumors were removed on day 41 for weight measurement, and the data revealed that tumor growth was indeed suppressed in the HH01-treated mouse group (Figure 5(c)). HH01 treatment also resulted in a significant reduction in tumor desmoplasia (Figure 5(d)) and serum HSP90α levels (Figure 5(e)). Taken together, these data suggest that HH01 antibody could be developed as a therapeutic agent to effectively treat desmoplastic PDAC.

[0079] Evaluation of the therapeutic efficacy of HH01 antibody in a desmoplastic humanized mouse PDAC transplant model We also evaluated the therapeutic efficacy of the HH01 antibody in a desmoplastic humanized mouse PDAC model. hHSC-engrafted ASID mice were subcutaneously inoculated with a mixture of human pancreatic adenocarcinoma PANC-1 cells with EndoMT-derived cells. Twenty days after inoculation, the mice were divided into three groups for further treatment (Figure 6(a)). Group A mice (n=3) were intravenously injected with 5 mg / kg per dose of control IgG for three doses at 7-day intervals. Group B mice (n=5) were injected with two doses of control IgG plus two doses of gemcitabine compared to group C mice (n=5) that were injected with two doses of HH01 antibody plus two doses of gemcitabine. Mice were administered the first 5 mg / kg of IgG (group B) or HH01 (group C) on day 20 after inoculation, and four days later, they were further intravenously injected with the first 100 mg / kg of gemcitabine. Two more doses of control IgG or HH01 antibody and one more dose of gemcitabine were administered at 7-day intervals, respectively (Figure 6(a)). The developing tumors were superficially measured every 3 days until day 39 after inoculation, and the tumor growth curves were plotted as in Figure 6(b). Compared to mice treated with IgG alone, mice treated with IgG plus gemcitabine had significantly suppressed tumors after the second gemcitabine administration. Meanwhile, in mice treated with HH01 plus gemcitabine, more effective suppression of tumor growth was observed only 4 days after injection of the first dose of HH01. The tumors further shrank after the second dose of gemcitabine and the third dose of HH01 were administered (Figure 6(b)). All mice were sacrificed on day 39, and tumors from mice treated with HH01 plus gemcitabine were significantly suppressed (Figure 6(c)). The combination of HH01 antibody with gemcitabine also showed strong efficacy in suppressing tumor desmoplasia (Figure 6(d)) and serum HSP90α levels (Figure 6(e)). These data supported that HH01 antibody could be an effective therapeutic agent targeting desmoplastic PDAC.

[0080] K-Ras G12D Evaluation of the therapeutic efficacy of HH01 antibody in an inducible fibrogenic mouse PDAC model Next, we evaluated the therapeutic efficacy of the HH01 antibody in a spontaneous PDAC mouse model. Clinically, more than 90% of PDAC patients harbor activated K-Ras mutants in their adenocarcinoma cells. In a transgenic mouse model, we identified activated mutant K-Ras in pancreatic duct cells. G12D Knock-in expression of pancreatic K-Ras induces PDAC development through the processes of ductal-to-ductal transformation (ADM), pancreatic intraepithelial neoplasia (PanIN), and consequently PDAC. G12DLSL-KrasG12D / Pdx1-Cre mice developed ADM as early as 3 months of age, and PDAC lesions at 6 months of age. Masson's trichrome staining revealed that small fibrotic areas were occasionally detected in the pancreatic tissues of 3-month-old LSL-KrasG12D / Pdx1-Cre mice, and extensive fibrosis was detected in the pancreatic tissues of LSL-KrasG12D / Pdx1-Cre mice aged 6 months or older, but not in LSL-KrasG12D control mice. To evaluate the therapeutic efficacy of the HH01 antibody, LSL-KrasG12D / Pdx1-Cre mice were not treated until they developed PDAC at 6 months of age. They were intravenously infused with 5 mg / kg per dose of control IgG or HH01 antibody on a schedule of 4 doses administered weekly, followed by 4 doses administered every other week, and finally 2 doses administered monthly for a total of 10 doses (Figure 7(a)). The entire experiment was endpointed at day 450, and survival curves of IgG or HH01 treated mice were plotted by Kaplan-Meier method (Figure 7(b)). Six out of seven IgG treated mice died before 450 days, while seven out of nine HH01 treated mice were still alive at day 450. The median survival times of IgG and HH01 treated mice were 344 and >450 days, respectively (p=0.004 by log-rank analysis). Unlike the smooth pancreatic morphology of normal C57BL / 6 mice or LSL-KrasG12D control mice, all LSL-KrasG12D / Pdx1-Cre mice had nodular pancreas whether the mice received HH01 treatment or not (Figure 7(c)). Meanwhile, Masson's trichrome staining revealed that pancreatic fibrosis was dramatically restored in those mice treated with HH01 and still alive at day 450 (Figure 7(c)). One IgG-treated mouse and one HH01-treated mouse were observed to have tumor nodules in the appearance of the liver, but nevertheless, the HH01-treated mice had apparently fewer nodules than the IgG-treated mice (Figure 7(c)). Masson's trichrome staining also revealed that the HH01-treated mice showed a significant improvement in liver fibrosis (Figure 7(c)).In addition, mouse serum samples were collected monthly, starting one day before the initiation of IgG or HH01 treatment. HSP90α levels in the final serum samples collected near the time of mouse death were compared with those in samples collected before IgG or HH01 treatment (i.e., pre-treatment vs. post-treatment). Our data showed that the elevated serum HSP90α levels in LSL-KrasG12D / Pdx1-Cre mice could be effectively abolished by HH01 treatment (Figure 7(d)).

[0081] Evaluation of the therapeutic efficacy of HH01 antibody in an M2-macrophage-driven mouse PDAC model To establish an M2-macrophage-associated mouse PDAC model, we mixed rHSP90α-treated BMDMs with Panc02 cells for subcutaneous inoculation into C57BL / 6 mice. For comparison with M1 macrophages, Panc02 cells plus LPS-treated BMDMs were inoculated into another group of mice. The graft growth of “Panc02+rHSP90α-treated BMDMs” started on day 6 after inoculation, and tumor growth continued at a faster rate than the other graft groups (Figure 8(a)). On day 30 after inoculation, all mice were sacrificed and their tumors were removed for weight measurement. As shown in Figure 8(b), rHSP90α-treated BMDMs significantly promoted Panc02 tumor growth, which was in contrast to the tumor-suppressing effect brought about by LPS-treated BMDMs. Immunohistochemical analysis showed that tumor tissues derived from the transplants of Panc02+rHSP90α-treated BMDMs expressed CD163, when compared with tumor masses from other groups of mice. + More cells but with significantly reduced levels of CD4 - Cells and CD8 + In the LPS-treated BMDM mice, the suppressed tumor tissues contained relatively high levels of CD4 + and CD8 + Nuclear staining with 4',6'-diamidino-2-phenylindole (DAPI) also showed elevated levels of chromatin condensation and nuclear fragmentation (Figure 8(d)), indicating that LPS-induced M1-macrophages were CD4 +and CD8 + These results suggested that eHSP90α-induced M2-type macrophages suppressed Panc02 tumor growth by recruiting immune cells and inducing more cell apoptosis. Therefore, these results concluded that eHSP90α-induced M2-type macrophages exhibited potent immunosuppressive and tumor-promoting activities. Furthermore, we evaluated the therapeutic efficacy of HH01 antibody in this M2 macrophage-promoted PDAC model. C57BL / 6 mice were subcutaneously inoculated with Panc02+rHSP90α-treated BMDM cell grafts. On the 27th day after inoculation, each mouse was implanted with approximately 0.1 cm 3 100 mice bearing 1000-μg / kg tumors and started to be treated with 5 mg / kg control IgG or HH01 antibody (Figure 9(a)). Considering the half-life of HH01 in mouse blood of more than 18.4 days, the effect of HH01 antibody was enhanced by a second dose after a 7-day interval. As shown in Figure 9(b), dramatic tumor shrinkage in HH01 treatment was observed as soon as 3 days later. All mice were sacrificed on day 42, and the results showed that tumors significantly shrank in HH01-treated mice when compared with those tumors that continued to grow in the control mouse group (p=0.001, Figure 9(c)). Consistently, the increase in serum HSP90α levels was also significantly suppressed after HH01 treatment (Figure 9(d)). Immunohistochemical analysis of tumor samples also showed that in accordance with the reduction of M2-macrophages in response to HH01 treatment, M2-macrophage-suppressive CD4 + and CD8 + The results showed that the cell level was effectively restored (Figure 9(e)). These results were supported by the results of immunohistofluorescence staining. F4 / 80 + iNOS + Increase in (M1) cells and F4 / 80 + Arginase 1 + A decrease in CD4 (M2) cells was observed in tissues from HH01-treated mice (Figures 10(a) and 10(b)). Consistently, + TNF-α + (Effective T) cells and CD8 + TNF-α +The levels of (cytotoxic T) cells were both increased in response to treatment with HH01 antibody (Figures 10(c) and 10(d)). These data suggest that HH01 antibody is an effective agent to suppress M2-macrophage-driven PDAC and improve the immune system of the tumor microenvironment.

[0082] conclusion Desmoplasia is a hallmark of many malignancies that is closely associated with rapid tumor growth, the occurrence of metastasis, and refractory treatment outcomes. Drugs and strategies targeting desmoplasia to mitigate malignant progression and improve therapeutic efficacy are an unmet medical need for cancer patients. Massive production of cancer-associated fibroblasts (CAFs) is one of the main causes of desmoplasia, and endothelial-mesenchymal transition (EndoMT) of endothelial cells provides a rich source for CAFs. EndoMT-derived CAFs recruit large amounts of bone marrow-derived macrophages into tumors and promote the polarization of these macrophages into the M2 type. M2 type macrophages not only secrete IL-10 and TGF-α to suppress effective T cells and cytotoxic T cells, but also produce VEGF, bFGF, and PDGF to stimulate tumor angiogenesis. Moreover, these M2 type macrophages express and secrete eHSP90α in large amounts, creating an eHSP90α-rich tumor microenvironment that has advantages for cancer cell proliferation and stemness acquisition. Therefore, eHSP90α and eHSP90α-rich tumor microenvironment may be regarded as novel cancer therapeutic targets. In our previous published results in mouse tumor models, EndoMT-derived CAFs significantly promoted tumor growth of pancreatic adenocarcinoma cell xenografts. Meanwhile, this EndoMT-promoted tumorigenesis was dramatically suppressed when mice were administered intravenous injection with mouse anti-HSP90α monoclonal antibody on or after the fourth day after cancer cell inoculation. We sequenced the gene of this mouse anti-HSP90α monoclonal antibody. After computer-assisted analysis and suggestions, we further constructed a humanized and improved antibody gene. The recombinant gene was introduced into ExpiCHO cells to express HH01, a humanized anti-HSP90α antibody. Through a series of analyses, we found that the HH01 antibody has a novel amino acid sequence in its CDR and is 1.87 × 10 -10 K of M DIt was found to show high binding affinity to eHSP90α at 100-fold increase in β-blockers (β-blockers) and β-blockers (β-blockers) values. HH01 antibody is not prone to form aggregates. It is highly water-soluble, but is not easily excreted from the mouse body due to its half-life in the blood longer than 18.4 days. It is not cytotoxic to retinal pigment epithelial cells and does not cause splenomegaly in mice. HH01 antibody also shows its superiority in anti-cancer function. It potently inhibits the invasive and spheroid-forming activities of pancreatic adenocarcinoma and colon cancer cell lines. Our results in three mouse cancer models reveal that HH01 antibody alone can abolish EndoMT-promoted desmoplastic tumor growth activity of subcutaneously inoculated pancreatic adenocarcinoma cell xenografts and can also show synergistic effects in combination with gemcitabine. In a transgenic mouse model of PDAC, it potently inhibits the development of pancreatic desmoplasia and adenocarcinoma caused by K-Ras mutations and liver metastasis, thus prolonging the survival time of experimental mice. Furthermore, in an M2-macrophage driven murine PDAC model, the HH01 antibody is also effective in suppressing tumor growth and improving tumor immunity.

[0083] All of the features disclosed in this specification may be combined in any combination. Each feature disclosed in this specification may be replaced by an alternative feature serving the same, equivalent or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is only an example of a generic series of equivalent or similar features.

[0084] Furthermore, from the above description, those skilled in the art will be able to easily ascertain the essential features of the present disclosure and make various modifications and variations of the present disclosure to adapt it to various applications and conditions without departing from the spirit and scope thereof. Accordingly, other embodiments are within the scope of the appended claims.

Claims

1. 1. An isolated antibody, comprising: An isolated antibody comprising a complementarity determining region (CDR) capable of specifically binding to an HSP90α epitope comprising the amino acid sequence EDK in the regions from amino acid 235 to amino acid 244 and amino acid 251 to amino acid 260.

2. heavy chain complementarity determining regions CDR1, CDR2 and CDR3 of the heavy chain variable region sequence of SEQ ID NO: 2 or SEQ ID NO: 12; light chain complementarity determining regions CDR1, CDR2 and CDR3 of the light chain variable region sequence of SEQ ID NO: 7 or SEQ ID NO: 17; 2. The isolated antibody of claim 1 , comprising:

3. 3. The isolated antibody of claim 2, wherein the heavy chain CDR1, CDR2 and CDR3 are according to SEQ ID NO: 2, and the light chain CDR1, CDR2 and CDR3 are according to SEQ ID NO:

7.

4. 4. The isolated antibody of claim 3, comprising a heavy chain variable region that is at least 80% identical to the sequence of SEQ ID NO:2 and a light chain variable region that is at least 80% identical to the sequence of SEQ ID NO:

7.

5. 4. The isolated antibody of claim 3, wherein the heavy chain CDR1 has the sequence of SEQ ID NO: 3, the heavy chain CDR2 has the sequence of SEQ ID NO: 4, the heavy chain CDR3 has the sequence of SEQ ID NO: 5, the light chain CDR1 has the sequence of SEQ ID NO: 8, the light chain CDR2 has the sequence of SEQ ID NO: 9, and the light chain CDR3 has the sequence of SEQ ID NO:

10.

6. 3. The isolated antibody of claim 2, wherein the heavy chain CDR1, CDR2 and CDR3 are according to SEQ ID NO: 12, and the light chain CDR1, CDR2 and CDR3 are according to SEQ ID NO:

17.

7. 7. The isolated antibody of claim 6, comprising a heavy chain variable region that is at least 80% identical to the sequence of SEQ ID NO:12 and a light chain variable region that is at least 80% identical to the sequence of SEQ ID NO:

17.

8. 7. The isolated antibody of claim 6, wherein the heavy chain CDR1 has the sequence of SEQ ID NO: 13, the heavy chain CDR2 has the sequence of SEQ ID NO: 14, the heavy chain CDR3 has the sequence of SEQ ID NO: 15, the light chain CDR1 has the sequence of SEQ ID NO: 18, the light chain CDR2 has the sequence of SEQ ID NO: 19, and the light chain CDR3 has the sequence of SEQ ID NO:

20.

9. The isolated antibody of claim 1, which is an antibody comprising an Fc region, a Fab fragment, a Fab' fragment, an F(ab')2 fragment, a single chain antibody, an scFV multimer, a monoclonal antibody, a monovalent antibody, a multispecific antibody, a humanized antibody or a chimeric antibody.

10. A nucleic acid molecule comprising a nucleic acid sequence encoding the isolated antibody of any one of claims 1 to 9.

11. 11. A pharmaceutical composition comprising an isolated antibody according to any one of claims 1 to 9 or a nucleic acid molecule according to claim 10 and a pharma- ceutically acceptable carrier.

12. The pharmaceutical composition of claim 11, wherein the isolated antibody comprises the heavy chain CDR1 having the sequence of SEQ ID NO: 13, the heavy chain CDR2 having the sequence of SEQ ID NO: 14, the heavy chain CDR3 having the sequence of SEQ ID NO: 15, the light chain CDR1 having the sequence of SEQ ID NO: 18, the light chain CDR2 having the sequence of SEQ ID NO: 19, and the light chain CDR3 having the sequence of SEQ ID NO:

20.

13. A method for treating cancer in a subject, comprising administering to the subject an effective amount of an isolated antibody described in any one of claims 1 to 9 or a nucleic acid molecule described in claim 10.

14. The method of claim 13, wherein the isolated antibody comprises the heavy chain CDR1 having the sequence of SEQ ID NO: 13, the heavy chain CDR2 having the sequence of SEQ ID NO: 14, the heavy chain CDR3 having the sequence of SEQ ID NO: 15, the light chain CDR1 having the sequence of SEQ ID NO: 18, the light chain CDR2 having the sequence of SEQ ID NO: 19, and the light chain CDR3 having the sequence of SEQ ID NO:

20.

15. 14. The method of claim 13, wherein the cancer has desmoplastic characteristics.

16. The method of claim 13, wherein the cancer has an M2-macrophage-promoting characteristic.

17. 14. The method of claim 13, wherein the cancer is pancreatic cancer, colon cancer, breast cancer, liver cancer or lung cancer.

18. The method of claim 13 , further comprising administering a therapeutic agent to the subject.

19. 20. The method of claim 18, wherein the therapeutic agent is gemcitabine.

20. The method of claim 13, wherein blood HSP90α levels in the subject are detected using an isolated antibody described in any one of claims 1 to 9 to monitor tumor regression in the subject.

21. A method for treating fibrogenesis in a subject, comprising administering to the subject an effective amount of an isolated antibody described in any one of claims 1 to 9 or a nucleic acid molecule described in claim 10.

22. The method of claim 21, wherein the isolated antibody comprises the heavy chain CDR1 having the sequence of SEQ ID NO: 13, the heavy chain CDR2 having the sequence of SEQ ID NO: 14, the heavy chain CDR3 having the sequence of SEQ ID NO: 15, the light chain CDR1 having the sequence of SEQ ID NO: 18, the light chain CDR2 having the sequence of SEQ ID NO: 19, and the light chain CDR3 having the sequence of SEQ ID NO:

20.

23. The method of claim 21, wherein blood HSP90α levels in the subject are detected using an isolated antibody described in any one of claims 1 to 9 to monitor tumor regression in the subject.

24. A method of treating cancer desmoplasia in a subject, comprising administering to the subject a therapeutic agent that targets eHSP90α.

Citation Information

Patent Citations

  • Human HSP90 alpha-2 antigen epitope peptide, HSP90 alpha-2 antigen, HSP90 alpha-2 antibody, HSP90 alpha-2 kit and application

    CN105669836A